Fiera Capital Corp Sells 13,112 Shares of Insmed Incorporated (NASDAQ:INSM)

Fiera Capital Corp reduced its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 2.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 592,415 shares of the biopharmaceutical company's stock after selling 13,112 shares during the quarter. Fiera Capital Corp owned 0.34% of Insmed worth $43,246,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. V Square Quantitative Management LLC acquired a new stake in Insmed in the 3rd quarter valued at about $30,000. GAMMA Investing LLC grew its holdings in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 224 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 287 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock worth $55,000 after buying an additional 627 shares during the period. Finally, EntryPoint Capital LLC acquired a new stake in shares of Insmed in the 1st quarter valued at $33,000.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on INSM shares. Bank of America raised their price objective on Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. StockNews.com cut shares of Insmed from a "hold" rating to a "sell" rating in a research note on Friday, August 9th. UBS Group raised their price target on Insmed from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, August 9th. JPMorgan Chase & Co. increased their target price on Insmed from $72.00 to $74.00 and gave the company an "overweight" rating in a report on Thursday, October 3rd. Finally, Morgan Stanley lifted their price target on shares of Insmed from $60.00 to $85.00 and gave the stock an "overweight" rating in a report on Friday, July 12th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $83.07.

Insider Transactions at Insmed

In other news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now owns 106,134 shares of the company's stock, valued at $7,951,559.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Michael Alexander Smith sold 27,871 shares of the company's stock in a transaction on Friday, September 13th. The stock was sold at an average price of $74.35, for a total value of $2,072,208.85. Following the sale, the insider now directly owns 67,856 shares of the company's stock, valued at $5,045,093.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Martina M.D. Flammer sold 13,436 shares of the company's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock worth $5,765,446 over the last quarter. Corporate insiders own 4.60% of the company's stock.

Insmed Trading Up 2.6 %

Insmed stock traded up $1.85 during trading hours on Friday, reaching $73.54. 1,121,834 shares of the company's stock were exchanged, compared to its average volume of 2,259,210. The firm has a market capitalization of $13.16 billion, a PE ratio of -13.25 and a beta of 1.12. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm's 50 day simple moving average is $72.51 and its 200 day simple moving average is $62.86. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. During the same period in the prior year, the company earned ($1.10) EPS. Insmed's revenue was up 18.1% on a year-over-year basis. Research analysts predict that Insmed Incorporated will post -5.52 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.